CG Oncology (NASDAQ:CGON) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of CG Oncology (NASDAQ:CGON) in a report published on Thursday morning, Benzinga reports. They currently have a $75.00 price objective on the stock.

A number of other brokerages also recently commented on CGON. Morgan Stanley initiated coverage on CG Oncology in a research note on Tuesday, February 20th. They set an overweight rating and a $55.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set a neutral rating and a $42.00 price target for the company. Finally, HC Wainwright reissued a buy rating and set a $75.00 target price on shares of CG Oncology in a research note on Thursday, April 4th.

CG Oncology Stock Down 8.2 %

NASDAQ CGON traded down $3.23 during trading hours on Thursday, reaching $36.27. The company’s stock had a trading volume of 2,443,166 shares, compared to its average volume of 390,521. The company has a 50-day moving average of $39.63. CG Oncology has a 52 week low of $28.55 and a 52 week high of $50.23.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CG Oncology stock. BNP Paribas Financial Markets acquired a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 11,198 shares of the company’s stock, valued at approximately $492,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.